Primecap Management Co. CA Increases Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Primecap Management Co. CA boosted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 0.2% in the third quarter, HoldingsChannel reports. The institutional investor owned 325,956 shares of the medical research company’s stock after buying an additional 780 shares during the quarter. Primecap Management Co. CA’s holdings in IQVIA were worth $77,242,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Versant Capital Management Inc lifted its position in shares of IQVIA by 733.3% during the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 110 shares in the last quarter. Opal Wealth Advisors LLC purchased a new stake in IQVIA in the 2nd quarter valued at about $27,000. Capital Performance Advisors LLP bought a new position in shares of IQVIA during the 3rd quarter worth approximately $27,000. Park Place Capital Corp purchased a new position in shares of IQVIA in the 3rd quarter worth approximately $28,000. Finally, Itau Unibanco Holding S.A. bought a new position in shares of IQVIA in the second quarter valued at approximately $29,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Stock Performance

NYSE:IQV opened at $197.57 on Friday. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The business’s fifty day moving average is $223.40 and its 200 day moving average is $227.35. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The firm has a market cap of $35.86 billion, a price-to-earnings ratio of 25.93, a PEG ratio of 1.97 and a beta of 1.51.

Insider Activity

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the transaction, the insider now directly owns 19,536 shares of the company’s stock, valued at $4,812,302.88. This trade represents a 6.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 1.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Leerink Partners reiterated an “outperform” rating and set a $248.00 price target (down from $260.00) on shares of IQVIA in a report on Tuesday. Redburn Atlantic started coverage on shares of IQVIA in a report on Monday, October 14th. They issued a “buy” rating and a $276.00 price target on the stock. Barclays decreased their price objective on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a report on Friday, November 1st. The Goldman Sachs Group dropped their target price on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, Robert W. Baird decreased their price target on shares of IQVIA from $256.00 to $223.00 and set a “neutral” rating for the company in a research note on Friday, November 1st. Four analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $256.50.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.